Helping Patients with Advanced Melanoma by Testing New Treatment Combinations
NCT06697301 · RecruitingThis study looks at the safety and effectiveness of a new drug called EIK1001 when given with Pembrolizumab for patients with advanced melanoma. The goal is to see how well this combination works compared to just Pembrolizumab with a placebo. Participants will be monitored over time to understand how these treatments help control the cancer.
Locations and contact
This trial is running at 107 locations. The first 8 are listed here.
- Ironwood Cancer & Research CentersChandler, ArizonaRecruiting
- Genesis Cancer and Blood InstituteHot Springs, ArkansasRecruiting
- Helios Clinical ResearchLos Angeles, CaliforniaRecruiting
- Providence Medical FoundationSanta Rosa, CaliforniaRecruiting
- UCHealth Memorial Hospital CentralColorado Springs, ColoradoRecruiting
- Bioresearch PartnerHialeah, FloridaRecruiting
- The Center for Cancer and Blood DisordersBethesda, MarylandRecruiting
- MidAmerica Cancer CareKansas City, MissouriRecruiting
Who can join
This trial is open to adults aged 18 and older, including both men and women, who have advanced melanoma that can be treated with Pembrolizumab. Participants need to be in good health overall and cannot have certain health issues like active autoimmune diseases or recent severe reactions to therapies. The trial team will confirm who is eligible to participate.
What happens during the trial
Participants will be divided into three groups by chance. One group will receive a placebo with Pembrolizumab. The second group will get EIK1001 combined with Pembrolizumab. The third group will receive a different dose of EIK1001 along with Pembrolizumab. Everyone will be monitored for their health and any side effects during the study.
The trial team
The trial is sponsored by Eikon Therapeutics, with collaboration from Merck Sharp & Dohme LLC. The study directors are Etah Kurland and Muaz Sadeia from Eikon Therapeutics.
Important dates
This trial started on May 22, 2025, and is still recruiting new participants. It is expected to finish in December 2040, with the primary results expected by December 2035.
Additional information
The trial's ID number is NCT06697301. It is in Phase 2 and Phase 3, which means it is looking at how well the treatment works and how safe it is. The study is FDA-regulated and aims to include about 740 participants.
Other recruiting trials for the same condition, with the eligibility rules written in plain language.
Browse similar trials →Find a top oncologist who can tell you whether a trial is a sensible option for you.
Find a doctor →The cancer centers running studies like this one, and what each is known for.
Browse hospitals →